Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 384 articles:
HTML format
Text format



Single Articles


    January 2019
  1. ZLOTTA AR, Kuk C
    Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men.
    Eur Urol. 2019 Jan 11. pii: S0302-2838(18)31046.
    PubMed     Text format    


  2. CARNEIRO B, Dizon DS
    Prostate Cancer Social Media: In YouTube We Trust?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(19)30005.
    PubMed     Text format    


  3. SOORIAKUMARAN P, Pavan N, Wiklund PN, Roach M 3rd, et al
    Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(18)31040.
    PubMed     Text format    


  4. KENFIELD SA, Van Blarigan EL, Ameli N, Lavaki E, et al
    Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31048.
    PubMed     Text format     Abstract available


  5. VANDEKERKHOVE G, Struss WJ, Annala M, Kallio HML, et al
    Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31050.
    PubMed     Text format     Abstract available


  6. SHAH TT, Peters M, Eldred-Evans D, Miah S, et al
    Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
    Eur Urol. 2019 Jan 8. pii: S0302-2838(18)31036.
    PubMed     Text format     Abstract available


  7. MURPHY DG, Azad AA, Sandhu S, Violet J, et al
    Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31047.
    PubMed     Text format    


  8. CIRIACO P, Briganti A, Bernabei A, Gandaglia G, et al
    Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31035.
    PubMed     Text format     Abstract available


  9. VIS AN, Boeve LMS
    Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31029.
    PubMed     Text format    


  10. KRETSCHMER A, Gleave ME
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE).
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31043.
    PubMed     Text format    


  11. HEIDEGGER I, Pichler R
    Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asia
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31049.
    PubMed     Text format    


  12. YANG DD, Mahal BA, Muralidhar V, Martin NE, et al
    Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Eur Urol. 2019;75:35-41.
    PubMed     Text format     Abstract available


    December 2018
  13. KHALAF DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, et al
    Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31020.
    PubMed     Text format     Abstract available


  14. DI LORENZO G, Buonerba C
    Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)30998.
    PubMed     Text format     Abstract available


  15. GREGUCCI F, Fiorentino A
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31030.
    PubMed     Text format    


  16. DENTON BT, Hawley ST, Morgan TM
    Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making.
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30965.
    PubMed     Text format    


  17. LOHAUS F, Zophel K, Lock S, Wirth M, et al
    Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30954.
    PubMed     Text format     Abstract available


  18. MATTA R, Chapple CR, Fisch M, Heidenreich A, et al
    Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)30962.
    PubMed     Text format     Abstract available


  19. OSTERGREN PB, Murtola TJ, Fode M
    Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)31021.
    PubMed     Text format    


  20. PADHANI AR, Haider MA, Villers A, Barentsz JO, et al
    Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)30963.
    PubMed     Text format    


  21. WEI Y, Li T, Liu L
    Re: Alberto Briganti, Nicola Fossati, James W.F. Catto, et al. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:357-68.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)31001.
    PubMed     Text format    


  22. GOKCE A, Gul D
    Re: Mark Douglas Tyson II, Tatsuki Koyama, Dan Lee, et al. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol 2018;74:26-33.
    Eur Urol. 2018 Dec 14. pii: S0302-2838(18)31000.
    PubMed     Text format    


  23. DAL PRA A, Abramowitz M, Pollack A
    Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30958.
    PubMed     Text format    


  24. HAMID AA, Gray KP, Shaw G, MacConaill LE, et al
    Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30949.
    PubMed     Text format     Abstract available


  25. NYBERG T, Govindasami K, Leslie G, Dadaev T, et al
    Homeobox B13 G84E Mutation and Prostate Cancer Risk.
    Eur Urol. 2018 Dec 7. pii: S0302-2838(18)30872.
    PubMed     Text format     Abstract available


  26. XIAO G, Yao J, Kong D, Ye C, et al
    The Long Noncoding RNA TTTY15, Which Is Located on the Y Chromosome, Promotes Prostate Cancer Progression by Sponging let-7.
    Eur Urol. 2018 Dec 7. pii: S0302-2838(18)30869.
    PubMed     Text format     Abstract available


  27. RUD E, Lauritzen P, Baco E
    Re: Henrik Gronberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.06.022.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30951.
    PubMed     Text format    


  28. BASCH EM, Scholz M, de Bono JS, Vogelzang N, et al
    Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30932.
    PubMed     Text format     Abstract available


  29. BURNS JA, Weiner AB, Catalona WJ, Li EV, et al
    Inflammatory Bowel Disease and the Risk of Prostate Cancer.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30938.
    PubMed     Text format     Abstract available


  30. WEGELIN O, Exterkate L, van der Leest M, Kummer JA, et al
    The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Eur Urol. 2018 Dec 3. pii: S0302-2838(18)30939.
    PubMed     Text format     Abstract available


  31. EKLUND M, Strom P, Gronberg H, Nordstrom T, et al
    Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Gronberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance
    Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30950.
    PubMed     Text format    


  32. SARTOR O
    Synergistic Interactions: Targeted Radiopharmaceuticals and Homologous Recombination Repair Alterations in Prostate Cancer.
    Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30940.
    PubMed     Text format    


    November 2018
  33. JOHNSON DC, Raman SS, Mirak SA, Kwan L, et al
    Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30930.
    PubMed     Text format     Abstract available


  34. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostat
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30942.
    PubMed     Text format    


  35. BOEVE LMS, Vis AN
    Reply to Herney Andres Garcia-Perdomo's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurr
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30933.
    PubMed     Text format    


  36. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30941.
    PubMed     Text format    


  37. HAMID S, Donaldson IA, Hu Y, Rodell R, et al
    The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification.
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30592.
    PubMed     Text format     Abstract available


  38. DE BRUYCKER A, De Bleser E, Decaestecker K, Fonteyne V, et al
    Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
    Eur Urol. 2018 Nov 28. pii: S0302-2838(18)30839.
    PubMed     Text format     Abstract available


  39. FIORENTINO A, Errico A, Scarcia M
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30881.
    PubMed     Text format    


  40. LOEB S, Sengupta S, Butaney M, Macaluso JN Jr, et al
    Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30854.
    PubMed     Text format     Abstract available


  41. ZHOU Z, Zhou Y, Yan W
    Re: Stephanie Guillaumier, Max Peters, Manit Arya, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 2018;74:422-9.
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30935.
    PubMed     Text format    


  42. BECKMANN K, Garmo H, Adolfsson J, Bosco C, et al
    Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Eur Urol. 2018 Nov 26. pii: S0302-2838(18)30879.
    PubMed     Text format     Abstract available


  43. GARCIA-PERDOMO HA
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Nov 23. pii: S0302-2838(18)30929.
    PubMed     Text format    


  44. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    PubMed     Text format    


  45. LAM TBL, MacLennan S, Plass K, Willemse PM, et al
    Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30866.
    PubMed     Text format    


  46. HECK MM, Tauber R, Schwaiger S, Retz M, et al
    Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30873.
    PubMed     Text format     Abstract available


  47. CIMADAMORE A, Scarpelli M, Santoni M, Cheng L, et al
    Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vas
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30895.
    PubMed     Text format    


  48. BOEVE LMS, Verhagen PCMS, Vis AN
    Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Th
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30864.
    PubMed     Text format    


  49. TILKI D, Evans CP
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30868.
    PubMed     Text format    


  50. MAHON KL, Qu W, Lin HM, Spielman C, et al
    Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30855.
    PubMed     Text format     Abstract available


  51. MATEO J, Carles J
    Towards a New Classification for Metastatic Prostate Cancer.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30862.
    PubMed     Text format    


  52. SHINDE A, Li R, Amini A, Glaser S, et al
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Nov 18. pii: S0302-2838(18)30865.
    PubMed     Text format    


  53. O'SULLIVAN JM, Heinrich D, James ND, Nilsson S, et al
    The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Nov 16. pii: S0302-2838(18)30857.
    PubMed     Text format    


  54. DE MAN K, Ost P
    Re: [(177)Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.
    Eur Urol. 2018 Nov 14. pii: S0302-2838(18)30859.
    PubMed     Text format    


  55. SATHIANATHEN NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, et al
    Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Eur Urol. 2018 Nov 10. pii: S0302-2838(18)30853.
    PubMed     Text format     Abstract available


  56. BERG S, Cole AP, Krimphove MJ, Nabi J, et al
    Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.
    Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30820.
    PubMed     Text format     Abstract available


  57. OSSES DF, Remmers S, Schroder FH, van der Kwast T, et al
    Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
    Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30851.
    PubMed     Text format     Abstract available


  58. GANDAGLIA G, Soligo M, Battaglia A, Muilwijk T, et al
    Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30837.
    PubMed     Text format     Abstract available


  59. CHIU PK, Ng CF, Semjonow A, Zhu Y, et al
    A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.
    Eur Urol. 2018 Nov 2. pii: S0302-2838(18)30842.
    PubMed     Text format     Abstract available


    October 2018
  60. CANTER DJ, Reid J, Latsis M, Variano M, et al
    Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30816.
    PubMed     Text format     Abstract available


  61. PLOUSSARD G, Gandaglia G, Borgmann H, de Visschere P, et al
    Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30836.
    PubMed     Text format     Abstract available


  62. BRATT O, Lamb AD
    Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer.
    Eur Urol. 2018 Oct 29. pii: S0302-2838(18)30807.
    PubMed     Text format    


  63. ROOBOL MJ
    Active Surveillance for Low-risk Prostate Cancer: Will it Become Obsolete?
    Eur Urol. 2018 Oct 25. pii: S0302-2838(18)30809.
    PubMed     Text format    


  64. GANDAGLIA G, Ploussard G, Valerio M, Mattei A, et al
    A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30753.
    PubMed     Text format     Abstract available


  65. VAN DEN BROECK T, van den Bergh RCN, Arfi N, Gross T, et al
    Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30752.
    PubMed     Text format     Abstract available


  66. ZAFEIRIOU Z, Bianchini D, Chandler R, Rescigno P, et al
    Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
    Eur Urol. 2018 Oct 16. pii: S0302-2838(18)30738.
    PubMed     Text format     Abstract available


  67. ANTONARAKIS ES, Shaukat F, Isaacsson Velho P, Kaur H, et al
    Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30750.
    PubMed     Text format     Abstract available


  68. KASIVISVANATHAN V, Ambrosi A, Giganti F, Chau E, et al
    A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI.
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30721.
    PubMed     Text format    


  69. VICKERS AJ, Lilja H, Assel M
    Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-u
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30743.
    PubMed     Text format    


  70. PENNEY KL, Loda M, Stampfer MJ
    Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
    Eur Urol. 2018 Oct 12. pii: S0302-2838(18)30744.
    PubMed     Text format    


  71. AUFFENBERG GB, Ghani KR, Ramani S, Usoro E, et al
    askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men.
    Eur Urol. 2018 Oct 11. pii: S0302-2838(18)30740.
    PubMed     Text format     Abstract available


  72. CARTER HB, Helfand B, Mamawala M, Wu Y, et al
    Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684.
    PubMed     Text format     Abstract available


  73. PERNAR CH, Ebot EM, Pettersson A, Graff RE, et al
    A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30730.
    PubMed     Text format     Abstract available


  74. FOSSATI N, Suardi N, Gandaglia G, Bravi CA, et al
    Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30659.
    PubMed     Text format     Abstract available


  75. MOSCHINI M, Zaffuto E, Karakiewicz PI, Andrea DD, et al
    External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722.
    PubMed     Text format     Abstract available


  76. ISAACSSON VELHO P, Qazi F, Hassan S, Carducci MA, et al
    Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729.
    PubMed     Text format     Abstract available


  77. CULIG Z
    Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30726.
    PubMed     Text format    


  78. SIVA S, Bressel M, Murphy DG, Shaw M, et al
    Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Eur Urol. 2018;74:455-462.
    PubMed     Text format     Abstract available


  79. TOSCO L, Briganti A, D'amico AV, Eastham J, et al
    Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
    Eur Urol. 2018 Oct 1. pii: S0302-2838(18)30549.
    PubMed     Text format     Abstract available


  80. OST P
    It Ain't Over Till the Fat Lady Sings: The POPSTAR Trial.
    Eur Urol. 2018;74:463-464.
    PubMed     Text format    


  81. GORIN MA, Walsh PC
    Magnetic Resonance Imaging Prior to First Prostate Biopsy-Are we there yet?
    Eur Urol. 2018;74:409-410.
    PubMed     Text format    


    September 2018
  82. NORDSTROM T, Lindberg J, Eklund M
    Towards Next-generation Urine-based Prostate Cancer Risk Stratification.
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30709.
    PubMed     Text format    


  83. OISHI M, Gill IS, Ashrafi AN, Lin-Brande M, et al
    Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30654.
    PubMed     Text format     Abstract available


  84. GRAFF RE, Kachuri L, Witte JS
    Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement.
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30681.
    PubMed     Text format    


  85. DEEK MP, Phillips RM, Haffner M, Tran PT, et al
    Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30715.
    PubMed     Text format    


  86. BOEVE LMS, Hulshof MCCM, Vis AN, Zwinderman AH, et al
    Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical
    Eur Urol. 2018 Sep 25. pii: S0302-2838(18)30658.
    PubMed     Text format     Abstract available


  87. SHINDE A, Li R, Glaser S, Amini A, et al
    Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30667.
    PubMed     Text format     Abstract available


  88. TONON L, Fromont G, Boyault S, Thomas E, et al
    Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
    Eur Urol. 2018 Sep 20. pii: S0302-2838(18)30618.
    PubMed     Text format     Abstract available


  89. MATTA R, Wallis CJD, Goldenberg MG, Hird AE, et al
    Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study.
    Eur Urol. 2018 Sep 18. pii: S0302-2838(18)30630.
    PubMed     Text format     Abstract available


  90. PRESTON MA, Gerke T, Carlsson SV, Signorello L, et al
    Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30627.
    PubMed     Text format     Abstract available


  91. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Posi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30645.
    PubMed     Text format    


  92. MCKIERNAN J, Donovan MJ, Margolis E, Partin A, et al
    A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30604.
    PubMed     Text format     Abstract available


  93. WEINER AB, Schaeffer EM, Eggener SE
    "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30643.
    PubMed     Text format    


  94. VALERIO M, Emberton M, Ahmed HU
    Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30646.
    PubMed     Text format    


  95. WALLIS CJD, Krakowsky Y, Finelli A
    Low Testosterone and Prostate Cancer: Is the Protection Real?
    Eur Urol. 2018 Sep 5. pii: S0302-2838(18)30616.
    PubMed     Text format    


  96. LOVF M, Zhao S, Axcrona U, Johannessen B, et al
    Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
    Eur Urol. 2018 Sep 1. pii: S0302-2838(18)30594.
    PubMed     Text format     Abstract available


  97. KENDALL MC
    Re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71.
    Eur Urol. 2018;74:e65.
    PubMed     Text format    


  98. PANG KH, Groves R, Catto JWF
    Reply to Mark C. Kendall's Letter to the Editor re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71.
    Eur Urol. 2018;74:e66.
    PubMed     Text format    


    August 2018
  99. ALLOTT EH, Freeman MR, Freedland SJ
    Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30597.
    PubMed     Text format    


  100. DALL'ERA MA, De Vere White RW
    New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose?
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30599.
    PubMed     Text format    


  101. GINSBURG KB, Auffenberg GB, Qi J, Powell IJ, et al
    Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30595.
    PubMed     Text format     Abstract available


  102. MASON M
    Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30563.
    PubMed     Text format    


  103. FONTEYNE V, Ost P
    Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers.
    Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30598.
    PubMed     Text format    


  104. REIS LO
    Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer?
    Eur Urol. 2018 Aug 28. pii: S0302-2838(18)30603.
    PubMed     Text format    


  105. FORSMARK A, Gehrman J, Angenete E, Bjartell A, et al
    Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
    Eur Urol. 2018 Aug 21. pii: S0302-2838(18)30560.
    PubMed     Text format     Abstract available


  106. MATEO J, Fizazi K, Gillessen S, Heidenreich A, et al
    Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Aug 14. pii: S0302-2838(18)30557.
    PubMed     Text format     Abstract available


  107. CIMADAMORE A, Scarpelli M, Cheng L, Lopez-Beltran A, et al
    Re: Isabel Rauscher, Charlotte Duwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Rec
    Eur Urol. 2018 Aug 6. pii: S0302-2838(18)30556.
    PubMed     Text format    


  108. MONTIRONI R, Cheng L, Cimadamore A, Lopez-Beltran A, et al
    Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?
    Eur Urol. 2018 Aug 6. pii: S0302-2838(18)30555.
    PubMed     Text format    


  109. ALBERTS AR, Roobol MJ, Verbeek JFM, Schoots IG, et al
    Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Eur Urol. 2018 Aug 3. pii: S0302-2838(18)30553.
    PubMed     Text format     Abstract available


  110. WATTS EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, et al
    Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
    Eur Urol. 2018 Aug 1. pii: S0302-2838(18)30546.
    PubMed     Text format     Abstract available


    July 2018
  111. BOUTROS PC
    The Promise and Perils of Sequencing Individual Prostate Cancer Nuclei.
    Eur Urol. 2018 Jul 31. pii: S0302-2838(18)30550.
    PubMed     Text format    


  112. D'ANDREA D, Shariat SF, Soria F
    Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Eur Urol. 2018 Jul 30. pii: S0302-2838(18)30544.
    PubMed     Text format    


  113. PREISSER F, Mazzone E, Nazzani S, Bandini M, et al
    Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Eur Urol. 2018 Jul 20. pii: S0302-2838(18)30484.
    PubMed     Text format     Abstract available


  114. CAVARRETTA I, Mancini N, Salonia A
    Analysis of the Enteric Microbiome: First Tentative Steps Towards a Comprehensive Work-up of Prostate Cancer?
    Eur Urol. 2018 Jul 20. pii: S0302-2838(18)30509.
    PubMed     Text format    


  115. MURTOLA TJ, Syvala H, Tolonen T, Helminen M, et al
    Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
    Eur Urol. 2018 Jul 18. pii: S0302-2838(18)30465.
    PubMed     Text format     Abstract available


  116. MODI PK, Morgan TM
    Tradeoffs in Refining the Diagnosis of Prostate Cancer.
    Eur Urol. 2018 Jul 18. pii: S0302-2838(18)30486.
    PubMed     Text format    


  117. COONEY KA, Beebe-Dimmer JL
    Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes.
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30479.
    PubMed     Text format    


  118. MAHAL BA, Yang DD, Nguyen PL
    Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. htt
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30471.
    PubMed     Text format    


  119. LAWRENCE MG, Obinata D, Sandhu S, Selth LA, et al
    Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
    Eur Urol. 2018 Jul 13. pii: S0302-2838(18)30445.
    PubMed     Text format     Abstract available


  120. CRABB SJ
    Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the Table.
    Eur Urol. 2018 Jul 12. pii: S0302-2838(18)30477.
    PubMed     Text format    


  121. LEPPERT JT, Brooks JD
    Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.01.043.
    Eur Urol. 2018 Jul 12. pii: S0302-2838(18)30472.
    PubMed     Text format    


  122. LISS MA, White JR, Goros M, Gelfond J, et al
    Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30461.
    PubMed     Text format     Abstract available


  123. MURPHY DG, Tilki D
    Getting the Balance Right-The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30463.
    PubMed     Text format    


  124. SWEENEY CJ
    Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30464.
    PubMed     Text format    


  125. GRONBERG H, Eklund M, Picker W, Aly M, et al
    Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2018 Jul 9. pii: S0302-2838(18)30447.
    PubMed     Text format     Abstract available


  126. LI W, Middha M, Bicak M, Sjoberg DD, et al
    Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Eur Urol. 2018 Jul 7. pii: S0302-2838(18)30446.
    PubMed     Text format     Abstract available


  127. NABID A, Carrier N, Martin AG, Bahary JP, et al
    Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
    Eur Urol. 2018 Jul 3. pii: S0302-2838(18)30443.
    PubMed     Text format     Abstract available


  128. XIE W, D'Amico AV
    Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death.
    Eur Urol. 2018 Jul 2. pii: S0302-2838(18)30451.
    PubMed     Text format    


  129. MOORE C
    Can Negative Prostate Magnetic Resonance Imaging Give Us the Reassurance We Need To Avoid Standard Biopsy? An Evidence-based Practical Approach.
    Eur Urol. 2018;74:55-56.
    PubMed     Text format    


    June 2018
  130. GUILLAUMIER S, Peters M, Arya M, Afzal N, et al
    A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30431.
    PubMed     Text format     Abstract available


  131. SU F, Zhang W, Zhang D, Zhang Y, et al
    Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Eur Urol. 2018 Jun 22. pii: S0302-2838(18)30430.
    PubMed     Text format     Abstract available


  132. BRIGANTI A, Fossati N, Catto JWF, Cornford P, et al
    Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jun 21. pii: S0302-2838(18)30433.
    PubMed     Text format     Abstract available


  133. HAIDL F, Pfister D, Heidenreich A
    Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients.
    Eur Urol. 2018 Jun 15. pii: S0302-2838(18)30419.
    PubMed     Text format    


  134. WILCZAK W, Wittmer C, Clauditz T, Minner S, et al
    Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
    Eur Urol. 2018 Jun 13. pii: S0302-2838(18)30423.
    PubMed     Text format     Abstract available


  135. SPRATT DE, Schaeffer EM
    Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.
    Eur Urol. 2018 Jun 12. pii: S0302-2838(18)30426.
    PubMed     Text format    


  136. AMINSHARIFI A, Polascik TJ
    Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer.
    Eur Urol. 2018 Jun 8. pii: S0302-2838(18)30420.
    PubMed     Text format    


  137. NAIR R, Porpiglia F, Zargar H
    Re: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis.
    Eur Urol. 2018 Jun 6. pii: S0302-2838(18)30418.
    PubMed     Text format    


  138. MEHRA N, Dolling D, de Bono J
    Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant P
    Eur Urol. 2018 Jun 1. pii: S0302-2838(18)30364.
    PubMed     Text format    


  139. BHINDI B, Karnes RJ
    Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Jun 1. pii: S0302-2838(18)30370.
    PubMed     Text format    


  140. MONTIRONI R, Cheng L, Lopez-Beltran A, Scarpelli M, et al
    Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy.
    Eur Urol. 2018;73:978-980.
    PubMed     Text format    


  141. LOMBARDO R, Bosch JLHR, Burkhard FC, Tubaro A, et al
    Re: A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control After Robotic Assisted Radical Prostatectomy.
    Eur Urol. 2018;73:980-981.
    PubMed     Text format    


  142. SPAHN M, Fehr JL
    Multiparametric Magnetic Resonance Imaging for Prostate-specific Antigen Recurrence After Radical Prostatectomy: Are We Leaving the "One Treatment Fits All Approach" and Moving Towards Personalized Imaging-guided Treatment?
    Eur Urol. 2018;73:888-889.
    PubMed     Text format    


  143. EGGENER S
    Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment.
    Eur Urol. 2018;73:897-898.
    PubMed     Text format    


    May 2018
  144. COOPERBERG MR, Erho N, Chan JM, Feng FY, et al
    The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
    Eur Urol. 2018 May 28. pii: S0302-2838(18)30362.
    PubMed     Text format     Abstract available


  145. CONTEDUCA V, Gurioli G, De Giorgi U
    Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press.
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30363.
    PubMed     Text format    


  146. LUGHEZZANI G, Buffi NM, Lazzeri M
    Diagnostic Pathway of Patients with a Clinical Suspicion of Prostate Cancer: Does One Size Fit All?
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30361.
    PubMed     Text format    


  147. DONOVAN JL, Hamdy FC
    Time for a "Radical" Change to Active Surveillance for Prostate Cancer?
    Eur Urol. 2018 May 17. pii: S0302-2838(18)30357.
    PubMed     Text format    


  148. VICKERS A, Nordstrom T, Assel M, Lilja H, et al
    Re: Tobias Nordstrom, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gronberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30333.
    PubMed     Text format    


  149. GONG J, Omlin A, Pal SK, Hsu J, et al
    Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30330.
    PubMed     Text format    


  150. KNIPPER S, Graefen M
    Palliative Radical Prostatectomy in Men with Metastatic Castration-resistant Prostate Cancer: Only When Your Back Is Against the Wall!
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30334.
    PubMed     Text format    


  151. CAMPODONICO F, Ennas M, Introini C
    Re: Ettore Di Trapani, Alessandro Nini, Irene Locatelli, et al. Development of the First Model of Radical Prostatectomy in the Mouse: A Feasibility Study. Eur Urol 2018;73:482-4.
    Eur Urol. 2018;73:e133.
    PubMed     Text format    


  152. AVULOVA S, Smith JA Jr
    Is Comparison of Robotic to Open Radical Prostatectomy Still Relevant?
    Eur Urol. 2018;73:672-673.
    PubMed     Text format    


  153. CHIN JL
    Re: Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.
    Eur Urol. 2018;73:808.
    PubMed     Text format    


  154. MONTIRONI R, Cheng L, Scarpelli M, Lopez-Beltran A, et al
    From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score.
    Eur Urol. 2018;73:684-686.
    PubMed     Text format    


    April 2018
  155. SANCHEZ-SALAS R, de la Rosette J, Polascik TJ, Carneiro A, et al
    Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients.
    Eur Urol. 2018 Apr 30. pii: S0302-2838(18)30320.
    PubMed     Text format     Abstract available


  156. ABDOLLAH F, Dalela D, Sood A, Keeley J, et al
    Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection.
    Eur Urol. 2018 Apr 29. pii: S0302-2838(18)30318.
    PubMed     Text format     Abstract available


  157. HEINRICH D, Russnes KM, Oldenburg J
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 21. pii: S0302-2838(18)30277.
    PubMed     Text format    


  158. TOUIJER K
    Reply to Pim J. van Leeuwen and Henk G. van der Poel's Letter to the Editor re: Karim A. Touijer, Robert J. Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative An
    Eur Urol. 2018 Apr 21. pii: S0302-2838(18)30259.
    PubMed     Text format    


  159. WALZ J
    Re: Surveillance or Metastasis-directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    Eur Urol. 2018 Apr 18. pii: S0302-2838(18)30255.
    PubMed     Text format    


  160. HAN S, Woo S, Kim YJ, Suh CH, et al
    Impact of (68)Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2018 Apr 17. pii: S0302-2838(18)30248.
    PubMed     Text format     Abstract available


  161. NUHN P, De Bono JS, Fizazi K, Freedland SJ, et al
    Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Eur Urol. 2018 Apr 16. pii: S0302-2838(18)30246.
    PubMed     Text format     Abstract available


  162. VAN LEEUWEN PJ, van der Poel HG
    Re: Karim A. Touijer, Robert Jeffery Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol. In p
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30258.
    PubMed     Text format    


  163. VAN STAM MA, van der Poel H
    The New Standard: Personalised Information about the Risks and Benefits of Treatment Strategies for Localised Prostate Cancer.
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30199.
    PubMed     Text format    


  164. REICHARD CA, Gregg JR, Achim MF, Aparicio AM, et al
    Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30249.
    PubMed     Text format     Abstract available


  165. ALCARAZ A, Mengual L
    Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30256.
    PubMed     Text format    


  166. HAIDL F, Heidenreich A, Pfister D
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 10. pii: S0302-2838(18)30247.
    PubMed     Text format    


  167. VILLERS A, Olivier J
    Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30242.
    PubMed     Text format    


  168. GIANNARINI G, Fossati N, Gandaglia G, Cucchiara V, et al
    Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30202.
    PubMed     Text format    


  169. MAURER T, Robu S, Schottelius M, Schwamborn K, et al
    (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30189.
    PubMed     Text format     Abstract available


  170. CARNEIRO A, Sanchez-Salas R
    Re: Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30204.
    PubMed     Text format    


  171. KAMRAN SC, Seisen T, Markt SC, Preston MA, et al
    Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cance
    Eur Urol. 2018;73:e96-e97.
    PubMed     Text format    


  172. HAJDINJAK T, Pelzer AE
    Re: What Are We Missing? False-negative Cancers at Multiparametric MR Imaging of the Prostate.
    Eur Urol. 2018;73:637.
    PubMed     Text format    


    March 2018
  173. LAVORGNA G, Montorsi F, Salonia A
    Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. Nat Genet 2018;50:219-28: Lipid Metabolism in Prostate Cancer: Expanding Patient Ther
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30181.
    PubMed     Text format    


  174. EKLUND M, Strom P, Nordstrom T, Gronberg H, et al
    Reply to Ola Bratt and Anna Ofverholm's Letter to the Editor re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. E
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30185.
    PubMed     Text format    


  175. TOSOIAN JJ, Lotan TL
    The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30188.
    PubMed     Text format    


  176. BRATT O, Ofverholm A
    Re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.0
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30186.
    PubMed     Text format    


  177. KINSELLA N, Stattin P, Cahill D, Brown C, et al
    Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30176.
    PubMed     Text format     Abstract available


  178. VAN SOEST RJ, Tombal B, Lolkema MP, de Wit R, et al
    Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30178.
    PubMed     Text format    


  179. PANEBIANCO V, Barchetti G, Simone G, Del Monte M, et al
    Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30183.
    PubMed     Text format     Abstract available


  180. HAO J, Ci X, Xue H, Wu R, et al
    Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Mar 12. pii: S0302-2838(18)30162.
    PubMed     Text format     Abstract available


  181. MONTGOMERY B, Lin DW
    Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding Road.
    Eur Urol. 2018 Mar 8. pii: S0302-2838(18)30164.
    PubMed     Text format    


  182. DAVIS ID
    Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2018 Mar 7. pii: S0302-2838(18)30163.
    PubMed     Text format    


  183. SJOBERG DD, Vickers AJ, Assel M, Dahlin A, et al
    Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Eur Urol. 2018 Mar 5. pii: S0302-2838(18)30126.
    PubMed     Text format     Abstract available


    February 2018
  184. TYSON MD 2ND, Koyama T, Lee D, Hoffman KE, et al
    Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Eur Urol. 2018 Feb 28. pii: S0302-2838(18)30119.
    PubMed     Text format     Abstract available


  185. MEHRA N, Dolling D, Sumanasuriya S, Christova R, et al
    Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Eur Urol. 2018 Feb 27. pii: S0302-2838(18)30120.
    PubMed     Text format     Abstract available


  186. MAHAL BA, Yang DD, Wang NQ, Alshalalfa M, et al
    Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Eur Urol. 2018 Feb 22. pii: S0302-2838(18)30098.
    PubMed     Text format     Abstract available


  187. GRAVIS G, Boher JM, Chen YH, Liu G, et al
    Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Eur Urol. 2018 Feb 20. pii: S0302-2838(18)30102.
    PubMed     Text format     Abstract available


  188. CHANDRASEKAR T, Ost P, Tilki D
    Is (68)Ga-Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?
    Eur Urol. 2018 Feb 19. pii: S0302-2838(18)30083.
    PubMed     Text format    


  189. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2.
    Eur Urol. 2018 Feb 17. pii: S0302-2838(18)30110.
    PubMed     Text format    


  190. AGGARWAL R
    Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30112.
    PubMed     Text format    


  191. LAMB AD, Bryant RJ, Mills IG, Hamdy FC, et al
    First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30114.
    PubMed     Text format    


  192. MOROTE J, Comas I, Planas J
    Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.
    Eur Urol. 2018 Feb 13. pii: S0302-2838(18)30093.
    PubMed     Text format    


  193. HAESE A
    Re: Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30086.
    PubMed     Text format    


  194. ANTONARAKIS ES, Lu C, Luber B, Liang C, et al
    Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30089.
    PubMed     Text format     Abstract available


  195. COOPERBERG MR, Brooks JD, Faino AV, Newcomb LF, et al
    Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30067.
    PubMed     Text format     Abstract available


  196. FAIENA I, Salmasi A, Pantuck AJ, Drakaki A, et al
    Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30077.
    PubMed     Text format    


  197. AMINSHARIFI A, Polascik TJ
    Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.
    Eur Urol. 2018 Feb 7. pii: S0302-2838(18)30076.
    PubMed     Text format    


  198. COOPERBERG MR
    How Should a Man with Prostate Cancer Choose his Surgeon?
    Eur Urol. 2018 Feb 3. pii: S0302-2838(18)30074.
    PubMed     Text format    


  199. WINTER A, Chavan A, Wawroschek F
    Magnetic Resonance Imaging of Sentinel Lymph Nodes Using Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer Patients: First-in-human Results.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30018.
    PubMed     Text format    


  200. TO SQ, Kwan EM, Fettke HC, Mant A, et al
    Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30016.
    PubMed     Text format     Abstract available


  201. PARKER C, Sydes MR
    Salvage Treatment After Radical Prostatectomy.
    Eur Urol. 2018;73:166-167.
    PubMed     Text format    


  202. CHIN JL
    Robotic-assisted Radical Prostatectomy for High-risk Cancer: Time for "Sexta-fecta".
    Eur Urol. 2018;73:224-225.
    PubMed     Text format    


  203. TILKI D, Evans CP
    The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy.
    Eur Urol. 2018;73:176-177.
    PubMed     Text format    


  204. BRZEZNIAK C, Oronsky B, Aggarwal R
    A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
    Eur Urol. 2018;73:306-307.
    PubMed     Text format    


  205. HERLEMANN A, Cowan JE, Carroll PR, Cooperberg MR, et al
    Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;73:215-223.
    PubMed     Text format     Abstract available


    January 2018
  206. TEMIZ MZ, Besiroglu H
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2018 Jan 31. pii: S0302-2838(18)30023.
    PubMed     Text format    


  207. KAPOOR DA
    Prostate Cancer Care and Practice Patterns: Low-quality Observations Miss the Benefits from High-quality Care.
    Eur Urol. 2018 Jan 30. pii: S0302-2838(18)30006.
    PubMed     Text format    


  208. MATEO J, Cheng HH, Beltran H, Dolling D, et al
    Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
    Eur Urol. 2018 Jan 29. pii: S0302-2838(18)30019.
    PubMed     Text format     Abstract available


  209. AHLGREN GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, et al
    Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30021.
    PubMed     Text format     Abstract available


  210. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30024.
    PubMed     Text format    


  211. RAUSCHER I, Duwel C, Haller B, Rischpler C, et al
    Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Eur Urol. 2018 Jan 18. pii: S0302-2838(18)30010.
    PubMed     Text format     Abstract available


  212. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jan 17. pii: S0302-2838(18)30005.
    PubMed     Text format     Abstract available


  213. STROM P, Nordstrom T, Gronberg H, Eklund M, et al
    The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Eur Urol. 2018 Jan 10. pii: S0302-2838(17)31096.
    PubMed     Text format     Abstract available


  214. UO T, Sprenger C
    Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward.
    Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31067.
    PubMed     Text format    


  215. LEE JK, Sjoberg DD, Miller MI, Vickers AJ, et al
    Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?
    Eur Urol. 2018;73:33-37.
    PubMed     Text format     Abstract available


  216. CULIG Z
    Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.
    Eur Urol. 2018;73:9-10.
    PubMed     Text format    


  217. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    PubMed     Text format    


  218. UREN AD, Cotterill N, Harding C, Hillary C, et al
    Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e15-e16.
    PubMed     Text format    


    December 2017
  219. BOSSI A
    Re: Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    Eur Urol. 2017 Dec 26. pii: S0302-2838(17)31046.
    PubMed     Text format    


  220. FRASER M, Boutros PC, Bristow RG
    A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31021.
    PubMed     Text format    


  221. ROACH M RD
    Re: Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31041.
    PubMed     Text format    


  222. ZHANG Q, Helfand BT, Carneiro BA, Qin W, et al
    Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-beta Insensitive Genetically Targeted CD8(+) T-cells Derived from Patients with Metastatic Castrate-resistant Disease.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31040.
    PubMed     Text format     Abstract available


  223. ROCCO B, Eissa A, Bianchi G
    Re: Positron Emission Tomography/Computed Tomography-based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31036.
    PubMed     Text format    


  224. OZEN H, Turkeri LN
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31044.
    PubMed     Text format    


  225. LUO J, Attard G, Balk SP, Bevan C, et al
    Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Eur Urol. 2017 Dec 16. pii: S0302-2838(17)31030.
    PubMed     Text format     Abstract available


  226. ROBINSON D, Garmo H, Lissbrant IF, Widmark A, et al
    Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.
    Eur Urol. 2017 Dec 15. pii: S0302-2838(17)31031.
    PubMed     Text format     Abstract available


  227. SPRATT DE, Dai DLY, Den RB, Troncoso P, et al
    Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31016.
    PubMed     Text format     Abstract available


  228. VALE C, Fisher D, Tierney J, White I, et al
    Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analy
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31019.
    PubMed     Text format    


  229. WALLIS CJD, Klaassen Z
    Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androge
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31020.
    PubMed     Text format    


  230. DONG L, Pienta KJ
    Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31023.
    PubMed     Text format    


    November 2017
  231. HAMDY FC, Lamb AD, Bryant RJ
    Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30994.
    PubMed     Text format    


  232. COOPERBERG MR
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30982.
    PubMed     Text format    


  233. ABDOLLAH F, Dalela D, Menon M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 22. pii: S0302-2838(17)30985.
    PubMed     Text format    


  234. LOEB S
    Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.
    Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30976.
    PubMed     Text format    


  235. CRUMBAKER M, Savdie R, Joshua AM
    Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.
    Eur Urol. 2017 Nov 18. pii: S0302-2838(17)30981.
    PubMed     Text format    


  236. MARTINI A, Gupta A, Cumarasamy S, Tewari AK, et al
    Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. In p
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30974.
    PubMed     Text format    


  237. LAMB AD, Bryant RJ, Camilleri P, Hamdy FC, et al
    Orient Expression: Solving the Mystery of Asian Prostate Cancer?
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30969.
    PubMed     Text format    


  238. LAVORGNA G, Montorsi F, Salonia A
    Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30973.
    PubMed     Text format    


  239. CUCCHIARA V, Cooperberg MR, Dall'Era M, Lin DW, et al
    Genomic Markers in Prostate Cancer Decision Making.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30975.
    PubMed     Text format     Abstract available


  240. TOMBAL B
    Assembling the Puzzle of Advanced Prostate Cancer: Lessons from GETUG-AFU 15.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30968.
    PubMed     Text format    


  241. AGGARWAL R
    Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30967.
    PubMed     Text format    


  242. RAMEY SJ, Agrawal S, Abramowitz MC, Moghanaki D, et al
    Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30900.
    PubMed     Text format     Abstract available


  243. CULINE S
    Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30907.
    PubMed     Text format    


  244. IBRAGIMOVA N, Zhanzak Z, Meyerbekova A, Xie Y, et al
    Re: Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Nov 4. pii: S0302-2838(17)30910.
    PubMed     Text format    


  245. MOTTET N, De Santis M, Briers E, Gillessen S, et al
    Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
    Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839.
    PubMed     Text format     Abstract available


    October 2017
  246. HEINZELBECKER J, Stockle M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30899.
    PubMed     Text format    


  247. SPRATT DE, Dess RT, Feng FY
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Can
    Eur Urol. 2017 Oct 27. pii: S0302-2838(17)30897.
    PubMed     Text format    


  248. LAVAUD P, Gravis G, Foulon S, Joly F, et al
    Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naive Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Eur Urol. 2017 Oct 23. pii: S0302-2838(17)30791.
    PubMed     Text format     Abstract available


  249. ASSEL M, Dahlin A, Ulmert D, Bergh A, et al
    Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Eur Urol. 2017 Oct 21. pii: S0302-2838(17)30860.
    PubMed     Text format     Abstract available


  250. SAITO K, Fujii Y
    Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.
    Eur Urol. 2017 Oct 20. pii: S0302-2838(17)30858.
    PubMed     Text format    


  251. GHADJAR P, Wiegel T
    Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017
    Eur Urol. 2017 Oct 19. pii: S0302-2838(17)30861.
    PubMed     Text format    


  252. GOOD DW, McNeill AS
    Re: Impact of Radical Prostatectomy on Long-term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.
    Eur Urol. 2017 Oct 17. pii: S0302-2838(17)30844.
    PubMed     Text format    


  253. VAN DER KWAST T
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30842.
    PubMed     Text format    


  254. TOUIJER KA, Karnes RJ, Passoni N, Sjoberg DD, et al
    Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30828.
    PubMed     Text format     Abstract available


  255. MCLEOD DG, Petrovics G
    Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30845.
    PubMed     Text format    


  256. WALLIS CJD, Klaassen Z, Bhindi B, Goldberg H, et al
    Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30849.
    PubMed     Text format     Abstract available


  257. SPAHN M
    Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30843.
    PubMed     Text format    


  258. PLOUSSARD G
    Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30841.
    PubMed     Text format    


  259. VAN DEN EEDEN SK, Lu R, Zhang N, Quesenberry CP Jr, et al
    A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Eur Urol. 2017 Oct 5. pii: S0302-2838(17)30777.
    PubMed     Text format     Abstract available


    September 2017
  260. WALZ J
    The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis?
    Eur Urol. 2017 Sep 28. pii: S0302-2838(17)30779.
    PubMed     Text format    


  261. PANSADORO V, Brassetti A
    Re: Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30782.
    PubMed     Text format    


  262. CAPOGROSSO P, Montorsi F
    Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30726.
    PubMed     Text format    


  263. GASSER T
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System.
    Eur Urol. 2017 Sep 20. pii: S0302-2838(17)30727.
    PubMed     Text format    


  264. MILLER K, Carles J, Gschwend JE, Van Poppel H, et al
    The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Eur Urol. 2017 Sep 19. pii: S0302-2838(17)30728.
    PubMed     Text format     Abstract available


  265. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30711.
    PubMed     Text format     Abstract available


  266. REN S, Wei GH, Liu D, Wang L, et al
    Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.
    Eur Urol. 2017 Sep 15. pii: S0302-2838(17)30720.
    PubMed     Text format     Abstract available


  267. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen Afte
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30719.
    PubMed     Text format    


  268. SEISEN T, Vetterlein MW, Karabon P, Jindal T, et al
    Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis.
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30697.
    PubMed     Text format     Abstract available


  269. DAL PRA A, Supiot S, Ghadjar P
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30718.
    PubMed     Text format    


    August 2017
  270. ZHU Y, Sharp A, Anderson CM, Silberstein JL, et al
    Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Aug 30. pii: S0302-2838(17)30695.
    PubMed     Text format     Abstract available


  271. GILLESSEN S, de Bono JS, Sartor O, Omlin AG, et al
    Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30700.
    PubMed     Text format    


  272. VON EYBEN FE, Virgolini I, Roviello G
    Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30696.
    PubMed     Text format    


  273. EGGER SJ, Calopedos RJ, O'Connell DL, Chambers SK, et al
    Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30699.
    PubMed     Text format     Abstract available


  274. TAKEDA T, Tin AL, Corradi RB, Mamoor M, et al
    Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30691.
    PubMed     Text format     Abstract available


  275. BORGMANN H, Lallous N, Ozistanbullu D, Beraldi E, et al
    Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30698.
    PubMed     Text format     Abstract available


  276. DE BONO JS, Chowdhury S, Feyerabend S, Elliott T, et al
    Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for >/=24 weeks in Europe.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30664.
    PubMed     Text format     Abstract available


  277. LOEB S, Zhou Q, Siebert U, Rochau U, et al
    Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30642.
    PubMed     Text format     Abstract available


  278. HOLLENBECK BK, Kaufman SR, Yan P, Herrel LA, et al
    Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
    Eur Urol. 2017 Aug 17. pii: S0302-2838(17)30687.
    PubMed     Text format     Abstract available


  279. SEITZ AK, Thoene S, Bietenbeck A, Nawroth R, et al
    AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Eur Urol. 2017 Aug 14. pii: S0302-2838(17)30653.
    PubMed     Text format     Abstract available


  280. WOO S, Suh CH, Kim SY
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cance
    Eur Urol. 2017 Aug 11. pii: S0302-2838(17)30669.
    PubMed     Text format    


  281. DEL RE M, Biasco E, Crucitta S, Derosa L, et al
    Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resi
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30663.
    PubMed     Text format    


  282. MESSINA C, Messina M, Boccardo F
    Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30659.
    PubMed     Text format    


  283. AYUBI E, Safiri S
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30668.
    PubMed     Text format    


  284. DE GIORGI U, Conteduca V, Scarpi E
    Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30661.
    PubMed     Text format    


  285. KLEIN EA
    Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30644.
    PubMed     Text format    


  286. DOWNER MK
    Why Epidemiological Studies of Physical Activity in Prostate Cancer Often Underestimate its Benefits.
    Eur Urol. 2017 Aug 3. pii: S0302-2838(17)30656.
    PubMed     Text format    


  287. FRIEDLANDER DF, Trinh QD, Krasnova A, Lipsitz SR, et al
    Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics.
    Eur Urol. 2017 Aug 1. pii: S0302-2838(17)30652.
    PubMed     Text format     Abstract available


    July 2017
  288. AGGARWAL R, Vigneron DB, Kurhanewicz J
    Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
    Eur Urol. 2017 Jul 29. pii: S0302-2838(17)30651.
    PubMed     Text format    


  289. AGGARWAL A, Lewis D, Charman SC, Mason M, et al
    Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition.
    Eur Urol. 2017 Jul 28. pii: S0302-2838(17)30601.
    PubMed     Text format     Abstract available


  290. LARDAS M, Liew M, van den Bergh RC, De Santis M, et al
    Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
    Eur Urol. 2017 Jul 27. pii: S0302-2838(17)30535.
    PubMed     Text format     Abstract available


  291. TREE A, Dearnaley D
    Randomised Controlled Trials Remain the Key to Progress in Localised Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30590.
    PubMed     Text format    


  292. CROOK J
    Optimal Radiotherapy for Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30589.
    PubMed     Text format    


  293. PENSON DF
    Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not.
    Eur Urol. 2017 Jul 20. pii: S0302-2838(17)30588.
    PubMed     Text format    


  294. CARAM MEV, Miller DC
    Treating Advanced Prostate Cancer-the Human Factor.
    Eur Urol. 2017 Jul 18. pii: S0302-2838(17)30585.
    PubMed     Text format    


  295. SPRATT DE, Dess RT, Zumsteg ZS, Lin DW, et al
    A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
    Eur Urol. 2017 Jul 14. pii: S0302-2838(17)30527.
    PubMed     Text format     Abstract available


  296. WANG Y, Jacobs EJ, Gapstur SM, Maliniak ML, et al
    Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
    Eur Urol. 2017 Jul 12. pii: S0302-2838(17)30537.
    PubMed     Text format     Abstract available


  297. PARKER CC, Coleman RE, Sartor O, Vogelzang NJ, et al
    Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516.
    PubMed     Text format     Abstract available


  298. LUO J, Luber B, Wang H, Antonarakis ES, et al
    Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30532.
    PubMed     Text format    


  299. GALFANO A, Secco S, Bocciardi AM
    Will Retzius-sparing Prostatectomy Be the Future of Prostate Cancer Surgery?
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30523.
    PubMed     Text format    


  300. KIM JH, Lee B, Chung BI
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 Jul 6. pii: S0302-2838(17)30524.
    PubMed     Text format    


  301. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and S
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30531.
    PubMed     Text format    


  302. JOHNSON SB, Lester-Coll NH, Kelly JR, Kann BH, et al
    Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30515.
    PubMed     Text format     Abstract available


  303. WOO S, Suh CH, Kim SY
    Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30525.
    PubMed     Text format    


  304. HABIBZADEH P, Habibzadeh F
    Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based
    Eur Urol. 2017 Jul 4. pii: S0302-2838(17)30528.
    PubMed     Text format    


    June 2017
  305. GILLESSEN S, Attard G, Beer TM, Beltran H, et al
    Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    Eur Urol. 2017 Jun 24. pii: S0302-2838(17)30497.
    PubMed     Text format     Abstract available


  306. ALBERTS AR, Schoots IG, Bokhorst LP, Drost FH, et al
    Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic R
    Eur Urol. 2017 Jun 21. pii: S0302-2838(17)30514.
    PubMed     Text format     Abstract available


  307. D'ANDREA D, Shariat SF
    Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Jun 20. pii: S0302-2838(17)30513.
    PubMed     Text format    


  308. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    Reply to Isabel Heidegger, Renate Pichler, and Andreas Pircher's Letter to the Editor re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relations
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30504.
    PubMed     Text format    


  309. TREE AC, Siva S, Ost P
    Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3.
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30506.
    PubMed     Text format    


  310. GANDAGLIA G, Boorjian SA, Parker WP, Zaffuto E, et al
    Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2017 Jun 13. pii: S0302-2838(17)30496.
    PubMed     Text format     Abstract available


  311. WALLIS CJD, Glaser A, Hu JC, Huland H, et al
    Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.
    Eur Urol. 2017 Jun 10. pii: S0302-2838(17)30495.
    PubMed     Text format     Abstract available


  312. HOYLE AP, Clarke NW
    Magnetic Resonance Imaging and Detection of Metastases in Prostate Cancer: Learning Lessons from History.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30492.
    PubMed     Text format    


  313. ALBERTSEN PC
    Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30485.
    PubMed     Text format    


  314. HEIDEGGER I, Pichler R, Pircher A
    Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30493.
    PubMed     Text format    


  315. CLARKE NW
    Re: Nicola Fossati, Peter-Paul M. Willemse, Thomas Van den Broeck, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. In Press. http://dx.doi.org
    Eur Urol. 2017 Jun 1. pii: S0302-2838(17)30410.
    PubMed     Text format    


  316. MANDEL P, Preisser F, Graefen M, Steuber T, et al
    High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy.
    Eur Urol. 2017;71:848-850.
    PubMed     Text format     Abstract available


  317. HEESAKKERS J, Farag F, Bauer RM, Sandhu J, et al
    Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review.
    Eur Urol. 2017;71:936-944.
    PubMed     Text format     Abstract available


    May 2017
  318. TROCK BJ, Karnes RJ
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 May 31. pii: S0302-2838(17)30464.
    PubMed     Text format    


  319. AYUBI E, Safiri S
    Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30465.
    PubMed     Text format    


  320. WOO S, Suh CH, Kim SY
    Reply to Thorsten Derlin, Christoph-A. von Klot, and Katja Hueper's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Met
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30470.
    PubMed     Text format    


  321. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30451.
    PubMed     Text format    


  322. DERLIN T, von Klot CA, Hueper K
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30469.
    PubMed     Text format    


  323. REICHARD CA, Chapin BF
    Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?
    Eur Urol. 2017 May 25. pii: S0302-2838(17)30404.
    PubMed     Text format    


  324. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30402.
    PubMed     Text format    


  325. COOPERBERG MR
    The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30401.
    PubMed     Text format     Abstract available


  326. WANG R, Sun Y, Li L, Niu Y, et al
    Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(R) to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30285.
    PubMed     Text format     Abstract available


  327. NGUYEN PL, Haddad Z, Ross AE, Martin NE, et al
    Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30390.
    PubMed     Text format     Abstract available


  328. HERMANNS T, Poyet C
    The Next Generation of Prostate Cancer Risk Calculators.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30387.
    PubMed     Text format    


  329. BECK M, Hayoz S, Ghadjar P
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30385.
    PubMed     Text format    


  330. HADASCHIK B, Herrmann K
    Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30388.
    PubMed     Text format    


  331. CHUA MLK, Lo W, Pintilie M, Murgic J, et al
    A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Eur Urol. 2017 May 13. pii: S0302-2838(17)30344.
    PubMed     Text format     Abstract available


  332. MITRAKAS L
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73.
    Eur Urol. 2017 May 10. pii: S0302-2838(17)30345.
    PubMed     Text format    


  333. MIRTTI T, Aittokallio T
    Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30340.
    PubMed     Text format    


  334. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prost
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30341.
    PubMed     Text format    


  335. LEAPMAN MS, Cowan JE, Simko J, Roberge G, et al
    Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
    Eur Urol. 2017;71:750-759.
    PubMed     Text format     Abstract available


  336. HE J, Albertsen PC, Moore D, Rotter D, et al
    Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
    Eur Urol. 2017;71:760-763.
    PubMed     Text format     Abstract available


  337. FROEHNER M, Koch R, Hubler M, Zastrow S, et al
    Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older.
    Eur Urol. 2017;71:710-713.
    PubMed     Text format     Abstract available


  338. BRAJTBORD JS, Leapman MS, Cooperberg MR
    The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.
    Eur Urol. 2017;71:705-709.
    PubMed     Text format     Abstract available


  339. TOSOIAN JJ, Almutairi F, Morais CL, Glavaris S, et al
    Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Eur Urol. 2017;71:697-700.
    PubMed     Text format     Abstract available


  340. KISHAN AU, Shaikh T, Wang PC, Reiter RE, et al
    Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Eur Urol. 2017;71:766-773.
    PubMed     Text format     Abstract available


  341. STUDENT V JR, Vidlar A, Grepl M, Hartmann I, et al
    Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy: One-year Functional Outcomes in a Two-group Randomised Controlled Trial.
    Eur Urol. 2017;71:822-830.
    PubMed     Text format     Abstract available


    April 2017
  342. YANG JC, Evans CP
    Adjunct Screening of NKX3.1 Expression Supports 5alpha-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.
    Eur Urol. 2017 Apr 25. pii: S0302-2838(17)30327.
    PubMed     Text format    


  343. PATEL DN, Freedland SJ
    New Prostate Cancer Biomarkers: The Search Continues.
    Eur Urol. 2017 Apr 24. pii: S0302-2838(17)30293.
    PubMed     Text format    


  344. WALSH PC
    The Search for the Missing Heritability of Prostate Cancer.
    Eur Urol. 2017 Apr 22. pii: S0302-2838(17)30283.
    PubMed     Text format     Abstract available


  345. GRUMMET JP, Plass K, N'Dow J
    Prostate Cancer Management in an Ageing Population.
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30290.
    PubMed     Text format    


  346. SOORIAKUMARAN P, Nyberg T, Akre O, Widmark A, et al
    Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Eur Urol. 2017 Apr 14. pii: S0302-2838(17)30282.
    PubMed     Text format     Abstract available


  347. SOOD A, Abdollah F
    Re: Diagnostic Accuracy of Multi-parametric Magnetic Resonance Imaging and Transrectal Ultrasound Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30275.
    PubMed     Text format    


  348. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30273.
    PubMed     Text format     Abstract available


  349. GANDAGLIA G, Fossati N, Zaffuto E, Bandini M, et al
    Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30280.
    PubMed     Text format     Abstract available


  350. WALKER SM, Knight LA, McCavigan AM, Logan GE, et al
    Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30238.
    PubMed     Text format     Abstract available


  351. RADTKE JP, Wiesenfarth M, Kesch C, Freitag MT, et al
    Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30267.
    PubMed     Text format     Abstract available


  352. KARNES RJ, Choeurng V, Ross AE, Schaeffer EM, et al
    Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264.
    PubMed     Text format     Abstract available


  353. KLEIN EA, Chait A, Hafron JM, Kernen KM, et al
    The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary
    Eur Urol. 2017 Apr 7. pii: S0302-2838(17)30236.
    PubMed     Text format     Abstract available



  354. Prostate Cancer and the John West Effect.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30095.
    PubMed     Text format     Abstract available


  355. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231.
    PubMed     Text format     Abstract available


  356. DUTTA A, Panja S, Virk RK, Kim JY, et al
    Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5alpha-reductase Inhibition.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30252.
    PubMed     Text format     Abstract available


  357. WEGELIN O, van Melick HHE, Hooft L, Bosch JLHR, et al
    Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Techniqu
    Eur Urol. 2017;71:517-531.
    PubMed     Text format     Abstract available


    March 2017
  358. SCHROECK FR, Jacobs BL, Bhayani SB, Nguyen PL, et al
    Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Eur Urol. 2017 Mar 30. pii: S0302-2838(17)30239.
    PubMed     Text format     Abstract available


  359. KIM JH, Khandwala YS, Chung BI
    Re: Jim C. Hu, David M. Nanus, Art Sedrakyan. Increase in prostate cancer metastases at radical prostatectomy in the United States. Eur Urol 2017;71:147-9.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30234.
    PubMed     Text format    


  360. SCHWEIZER MT, Antonarakis ES, Denmeade SR
    Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30233.
    PubMed     Text format     Abstract available


  361. PORTER LH, Lawrence MG, Ilic D, Clouston D, et al
    Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    Eur Urol. 2017 Mar 22. pii: S0302-2838(17)30178.
    PubMed     Text format     Abstract available


  362. LAMB BW, Violet J, Siva S, Murphy DG, et al
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30179.
    PubMed     Text format    


  363. MOLDOVAN PC, Van den Broeck T, Sylvester R, Marconi L, et al
    What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30115.
    PubMed     Text format     Abstract available


  364. MO F, Lin D, Takhar M, Ramnarine VR, et al
    Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Mar 19. pii: S0302-2838(17)30166.
    PubMed     Text format     Abstract available


  365. ALONGI F, Aiello D, Mazzola R, Cavalleri S, et al
    Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30169.
    PubMed     Text format    


  366. MOSCHINI M, Carroll PR, Eggener SE, Epstein JI, et al
    Low-risk Prostate Cancer: Identification, Management, and Outcomes.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30174.
    PubMed     Text format     Abstract available


  367. SMITH MR, Saad F, Rathkopf DE, Mulders PF, et al
    Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30172.
    PubMed     Text format     Abstract available


  368. ANTONARAKIS ES
    Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30167.
    PubMed     Text format    


  369. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Text format     Abstract available


  370. ADAM M, Tennstedt P, Lanwehr D, Tilki D, et al
    Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.
    Eur Urol. 2017;71:330-336.
    PubMed     Text format     Abstract available


  371. FOSSATI N, Wiklund P, Rochat CH, Montorsi F, et al
    Robotic and Open Radical Prostatectomy: The First Prospective Randomised Controlled Trial Fuels Debate Rather than Closing the Question.
    Eur Urol. 2017;71:307-308.
    PubMed     Text format     Abstract available


  372. DASKIVICH TJ, Spiegel B, Kim HL
    Online Ratings Systems for Physicians and Institutions: Limitations of the Current State of the Art.
    Eur Urol. 2017;71:311-312.
    PubMed     Text format     Abstract available


  373. BORGHESI M, Ahmed H, Nam R, Schaeffer E, et al
    Complications After Systematic, Random, and Image-guided Prostate Biopsy.
    Eur Urol. 2017;71:353-365.
    PubMed     Text format     Abstract available


  374. MUNGOVAN SF, Sandhu JS, Akin O, Smart NA, et al
    Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis.
    Eur Urol. 2017;71:368-378.
    PubMed     Text format     Abstract available


    February 2017
  375. GRANDE P, Di Pierro GB, Mordasini L, Ferrari M, et al
    Prospective Randomized Trial Comparing Titanium Clips to Bipolar Coagulation in Sealing Lymphatic Vessels During Pelvic Lymph Node Dissection at the Time of Robot-assisted Radical Prostatectomy.
    Eur Urol. 2017;71:155-158.
    PubMed     Text format     Abstract available


  376. MA TM, Tosoian JJ, Schaeffer EM, Landis P, et al
    The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Eur Urol. 2017;71:174-180.
    PubMed     Text format     Abstract available


  377. ALBERS P
    Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Eur Urol. 2017;71:300.
    PubMed     Text format    


  378. DAMSGAARD J, Joensen UN, Carlsen E, Erenpreiss J, et al
    Reply to Eugenio Ventimiglia, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Jakob Damsgaard, Ulla N. Joensen, Elisabeth Carlsen, et al. Varicocele Is Associated with Impaired Semen Quality and Reproductive Hormone Levels: A Study o
    Eur Urol. 2017;71:e71-e72.
    PubMed     Text format    


  379. STOLZENBURG JU, Kyriazis I, Liatsikos E
    Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach.
    Eur Urol. 2017;71:159-160.
    PubMed     Text format    


  380. PRADO K, Reiter RE
    Is Targeted Biopsy Applicable to Patients on Active Surveillance?
    Eur Urol. 2017;71:181-182.
    PubMed     Text format    


    January 2017
  381. VALERIO M, Cerantola Y, Eggener SE, Lepor H, et al
    New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.
    Eur Urol. 2017;71:17-34.
    PubMed     Text format     Abstract available


  382. SPRATT DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, et al
    Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.
    Eur Urol. 2017;71:37-43.
    PubMed     Text format     Abstract available


  383. NICITA G, Villari D, Caroassai Grisanti S, Marzocco M, et al
    Minimally Invasive Transanal Repair of Rectourethral Fistulas.
    Eur Urol. 2017;71:133-138.
    PubMed     Text format     Abstract available


  384. LI Y, Donmez N, Sahinalp C, Xie N, et al
    SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Eur Urol. 2017;71:68-78.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: